Get the Stockscreener App
0.5271
0.10%
0.0042
Context Therapeutics Inc stock is traded at $0.5271, with a volume of 690.27K.
It is up +0.10% in the last 24 hours and down -12.77% over the past month.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
See More
Previous Close:
$0.5229
Open:
$0.53
24h Volume:
690.27K
Relative Volume:
0.29
Market Cap:
$48.30M
Revenue:
-
Net Income/Loss:
$-40.23M
P/E Ratio:
-1.233
EPS:
-0.4275
Net Cash Flow:
$-34.82M
1W Performance:
+15.72%
1M Performance:
-12.77%
6M Performance:
-77.54%
1Y Performance:
-33.44%
1-Day Range:
$0.5156
$0.5346
1-Week Range:
$0.4522
$0.535
52-Week Range:
$0.432
$3.62
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267-225-7416
Address
2001 MARKET STREET, PHILADELPHIA
Compare CNTX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.5257 | 48.04M | 0 | -40.23M | -34.82M | -0.4275 |
VRTX
Vertex Pharmaceuticals Inc
|
514.89 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
807.61 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.05 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.65 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
361.72 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Guggenheim | Buy |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | JMP Securities | Mkt Outperform |
| Nov-25-24 | Initiated | D. Boral Capital | Buy |
| May-16-24 | Initiated | Piper Sandler | Overweight |
Context Therapeutics Inc Stock (CNTX) Latest News
a2026mar-contextxcorpdec.htm - SEC.gov
CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip - Stocktwits
MPM BioImpact reports 1.4% stake in Context Therapeutics (CNTX) common stock - Stock Titan
Context Therapeutics Inc. (CNTX) Stock Price, News, Quote & History - Yahoo Finance
Blue Owl Capital Holdings (CNTX) reports 3.19% beneficial stake in Context Therapeutics - Stock Titan
Context Therapeutics Narrows Pipeline as Quarterly Loss Widens - MyChesCo
Maxim Group Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Enterprise value to EBITDA forward of Context Therapeutics, Inc. – FWB:6K9 - TradingView
LifeSci Capital downgrades Context Therapeutics (CNTX) to a Hold - The Globe and Mail
Context Therapeutics Inc (CNTX) Stock News Today - TradingKey
Context Therapeutics Inc (CNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Context Therapeutics Inc. Stock 12‑Month Price Target Cut to $4.56, Implies 557% Upside - TradingView
Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move - Benzinga
Context Therapeutics (NASDAQ:CNTX) Announces Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat
Context Therapeutics Highlights Progress in T Cell Engager Pipeline - TipRanks
Context Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Context Therapeutics Q2 net loss widens on higher R&D costs - TradingView
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress - The Manila Times
Context Therapeutics Ends CT-95, Focuses on Two Cancer Programs - Stock Titan
Context Therapeutics Inc. 1H 2026: Net income $(23.24)M, Diluted EPS $(0.24) — 10-Q Summary - TradingView
Context Therapeutics (NASDAQ: CNTX) reports $23.2 million loss and cash runway - Stock Titan
CNTX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
CNTX: CTIM-76 and CT-202 prioritized; $43M cash funds operations into Q4 2027; net loss rises - TradingView
Weekly Recap: CNTX Nasdaq notice and Q2 2026 $0.09 loss forecast - TradingView
Context Therapeutics Receives Nasdaq Minimum Bid Price Notice - The Globe and Mail
Context Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Context Therapeutics (CNTX): Octagon group reports 3.3% beneficial stake in Schedule 13G/A - Stock Titan
Context Therapeutics (CNTX) Projected to Release Quarterly Earnings on Wednesday - MarketBeat
Context Therapeutics Inc (CNTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Context Therapeutics, Inc. Revenue Breakdown – FWB:6K9 - TradingView
CNTX|Context Therapeutics Inc|Price:0.603|Chg%:+0.003 - TradingKey
BlackRock (NYSE: BLK) discloses 6.7% ownership of Context Therapeutics (CNTX) - Stock Titan
Octagon Capital Advisors LP Takes $13.76 Million Position in Context Therapeutics Inc. $CNTX - MarketBeat
Context Therapeutics Inc (CNTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Context Therapeutics Inc (CNTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Context Therapeutics Inc (CNTX) Balance Sheet - TradingKey
Context Therapeutics Inc (CNTX) Income Statement - TradingKey
Context Therapeutics Inc (CNTX) Cash Flow - TradingKey
Context Therapeutics Inc (CNTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Context Therapeutics, Inc. Revenue Breakdown – DUS:6K9 - TradingView
Context Therapeutics Inc (CNTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Context Therapeutics Inc (CNTX) Earnings Date & Reports & Earnings News - TradingKey
Context Therapeutics Inc (CNTX) Institutional Confidence - TradingKey
Context Therapeutics, Inc. Revenue Breakdown – SWB:6K9 - TradingView
Context Therapeutics Inc. Revenue Breakdown – BOATS:CNTX - TradingView
Context Therapeutics Inc. (CNTX) Slips 2.7% as Shares Approach Key SupportGamma Squeeze - po-news-eg.net
Context Therapeutics (NASDAQ:CNTX) Lowered to Strong Sell Rating by Wall Street Zen - MarketBeat
CNTX Q1 2026 Earnings: Beat on EPS as Clinical Pipeline AdvancesEarnings Manipulation Risk - dars.gov.et
SRNE stock holds on Sorrento Therapeutics identity and filing context - ad-hoc-news.de
Context Therapeutics Inc. (CNTX) Q1 2026 Earnings: Narrowing Loss Beats Street Estimates, Stock Holds Steady - dars.gov.et
Enterprise value to revenue forward of Context Therapeutics, Inc. – DUS:6K9 - TradingView
Context Therapeutics Inc Stock (CNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.67%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):